


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1- 30 (Cancelled).

31. (Previously presented): A compound having the formula:



or a pharmaceutically acceptable salt thereof.

32. (Previously presented): A compound which is 3-phenylsulfonyl-8-piperazin-1-yl-quinoline.

33. (Currently amended): A method of treating a cognitive memory disorder which comprises administering a therapeutically effective amount of the compound, or pharmaceutically acceptable salt thereof, according to claim 31 to a [[patient]] human in need thereof, wherein the cognitive memory disorder is selected from age related cognitive decline, mild cognitive impairment, and cognitive deficits in schizophrenia.

34. (Currently amended): A method of treating a cognitive memory disorder which comprises administering a therapeutically effective amount of the compound according to claim 32 to a [[patient]] human in need thereof, wherein the cognitive memory disorder is selected from age related cognitive decline, mild cognitive impairment, and cognitive deficits in schizophrenia.

35. (Previously presented): A crystalline form of the compound according to claim 32, wherein said crystalline form provides an X-ray powder diffraction pattern substantially in accordance with Figure 6.

36. (Previously presented): A crystalline form of the compound according to claim 32, wherein said crystalline form provides a Raman spectrum substantially in accordance with Figure 5.

37. (Previously presented): A crystalline form of the compound according to claim 32, wherein said crystalline form provides an infra red spectrum substantially in accordance with Figure 4.

Claims 38-39 (Cancelled).

40. (Currently amended): A method of treating Alzheimers disease comprising administering a therapeutically effective amount of the compound, or pharmaceutically acceptable salt thereof, according to claim 31 to a [[patient]] human in need thereof.

41. (Currently amended): A method of treating Alzheimers disease comprising administering a therapeutically effective amount of the compound according to claim 32 to a [[patient]] human in need thereof.

42. (Currently amended): A pharmaceutical composition comprising the compound, or pharmaceutically acceptable salt thereof, according to claim 31 and a pharmaceutically acceptable carrier or excipient.

43. (Previously presented): A pharmaceutical composition comprising the compound according to claim 32 and a pharmaceutically acceptable carrier or excipient.